Invest Securities confirms its neutral rating on Biophytis shares, with an unchanged target price of 2.21 euros.

Biophytis has announced that it has obtained FDA approval to initiate its Ph II OBA study, which aims to reduce the loss of muscle mass and loss of mobility associated with GLP-1 products in obese people.

We anticipate raising funds in the short term to strengthen cash flow, with a view to initiating this Ph II trial in the very near future", says Invest.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.